Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Open-label Clinical Study of TIL Cells for the Treatment of the Recurrent/Metastatic Solid Tumors Patients Who Had Failed Standard Therapy

NCT05649618 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT05649618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05649618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Open-label Clinical Study of TIL Cells for the Treatment of the Recurrent/Metastatic Solid Tumors Patients Who Had Failed Standard Therapy
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
December 5, 2022
Completion date
March 31, 2026
Enrollment
42 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor